ArticleJAMA network open2022
Evaluation of Optimal Threshold of Neutrophil-Lymphocyte Ratio and Its Association With Survival Outcomes Among Patients With Head and Neck Cancer.
Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.Oral oncology · 2026Pooled it
- Neutrophil to lymphocyte ratio in Alzheimer's disease: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.American journal of clinical oncology · 2026Trial
- Treatment-related lymphopenia predicts long-term survival in locally advanced head and neck cancer:Frontiers in immunology · 2026Trial
- Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.BMC medicine · 2024Trial
- Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Recurrence in HPV-Associated Oropharyngeal Cancer After Transoral Robotic Surgery.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Inflammation mediates platinum-based chemotherapy-induced risk of adverse cardiac events in older NSCLC patients: a pilot study.Cardio-oncology (London, England) · 2026Article
- Article
- Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy.Cancer medicine · 2026Article
- Selection Criteria for De-Escalated Chemoradiotherapy for HPV-Related Oropharyngeal Cancer Based on Prognostic Biomarkers or Early Tumor Response to Therapy: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Establishment and evaluation of novel prognostic biomarkers based on systemic coagulation-inflammation index and related genes in breast cancer.Frontiers in immunology · 2026Article
- Deconstructing Risk: A Machine Learning-Guided Logistic Regression Model for Predicting Early Mucosal Edema Following Prophylactic Ileostomy in Elderly Rectal Cancer Patients.International journal of general medicine · 2026Article
- Article
- Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Treatment Toxicity and Intolerance in Operable Head and Neck Cancer: An Ambispective Cohort Study.Head & neck · 2025Article
- Inflammation as a mediator between neck adipose tissue and tumor aggressiveness in hypopharyngeal and laryngeal squamous cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Optimal cutpoint of preoperative neutrophil-lymphocyte ratio and associated postoperative prognosis in colorectal cancer patients.International journal of colorectal disease · 2025Article
- Development and validation of the systemic nutrition/inflammation index for improving perioperative management of non-small cell lung cancer.BMC medicine · 2025Article
- Impact of systemic immune-inflammation index and its evaluation of optimal threshold in patients with limited-stage small cell lung cancer: a retrospective study based on 572 cases.Translational cancer research · 2025Article
- Article
- Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Given the role of inflammation in cancer progression, neutrophil-lymphocyte ratio (NLR) from peripheral blood has been suggested as a readout of systemic inflammation and a prognostic marker in several solid malignant neoplasms. However, optimal threshold for NLR in US patients with head and neck cancer remains unclear. Objective: To evaluate the optimal NLR threshold as a potential prognostic biomarker for survival outcomes. Design, Setting, and Participants: This retrospective cohort study was conducted at a single institution. Participants included 496 patients with nonmetastatic head and neck cancer who underwent chemoradiation from April 2007 to March 2021. Statistical analysis was performed from September to December 2021. Exposures: High vs low NLR. Main Outcomes and Measures: Overall survival (OS) and cancer-specific survival (CSS). Results: A total of 496 patients (411 male patients [82.9%]; 432 White patients [87.1%]; 64 patients with other race or ethnicity [12.9%]; median [IQR] age, 61 [55-67] years) were identified. Median (IQR) follow-up was 44.4 (22.8-74.0) months. Thresholds of NLR for both OS and CSS were 5.71. High NLR above 5.71 was associated with worse OS (adjusted hazard ratio [aHR], 1.97; 95% CI, 1.26-3.09; P = .003) and CSS (aHR, 2.33; 95% CI, 1.38-3.95; P = .002). On logistic multivariable analysis, patients were more likely to have high NLR if they had higher T and N staging (T3-4: aOR, 4.07; 95% CI, 1.92-9.16; P < .001; N2: aOR, 2.97; 95% CI, 1.04-9.17; P = .049; N3: aOR, 11.21; 95% CI, 2.84-46.97; P < .001), but less likely if they had a good performance status (Karnofsky Performance Status 90-100: aOR, 0.29; 95% CI, 0.14-0.59; P < .001). Among 331 patients (66.7%) with available human papillomavirus (HPV) data, high NLR was not associated with OS (HPV-negative: aHR, 2.46; 95% CI, 0.96-6.31; P = .06; HPV-positive: aHR, 1.17; 95% CI, 0.38-3.56; P = .78) and CSS (HPV-negative: aHR, 2.55; 95% CI, 0.81-7.99; P = .11; HPV-positive: aHR, 1.45; 95% CI, 0.44-4.76; P = .54). Conclusions and Relevance: High NLR was associated with worse survival. Patients with substantial disease burden and poor performance status were more likely to have high NLR. These findings suggest that further studies would be warranted to investigate the role of such prognostic marker to identify patients at risk to tailor interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.